A Phase 2, Open-Label Study to Investigate the Efficacy and Safety of an 8-Week and 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 4 Hepatitis C Virus Infection With and Without Cirrhosis
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2016
Price : $35 *
At a glance
- Drugs Simeprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 23 Feb 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 22 Jun 2015 Planned End Date changed from 1 Aug 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.
- 22 Jun 2015 Planned primary completion date changed from 1 May 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.